Healthcare
Live Price
Offline$0.07
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 18, 2026
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
IXICO plc (PHYOF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.07 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +13.3%, EPS growth of +55.3%, a dividend yield of 0.0%. What stands out right now is revenue +13.3%, EPS +55.3%, free cash flow +14.8% with operating margin -34.9% and ROIC -12.9%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Stock Foundry combines PHYOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.3% vs +7.6% peer median
Operating Margin
Below sector median
-34.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +13.3% and EPS at +55.3%, with operating margin around -34.9%.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHYOF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PHYOF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for PHYOF and SPY.

Company Overview
IXICO plc
Other OTC
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.